NASDAQ: BDSXBiodesix Inc Stock
$6.56-1.04 (-13.68%)
Updated Sep 16, 2025
BDSX Price
$6.56
Fair Value Price
N/A
Market Cap
$48.10M
52 Week Low
$3.44
52 Week High
$37.00
P/E
-1.17x
P/B
42.26x
P/S
0.54x
PEG
N/A
Dividend Yield
N/A
Revenue
$76.56M
Earnings
-$41.08M
Gross Margin
78.8%
Operating Margin
-44.02%
Profit Margin
-53.7%
Debt to Equity
76.1
Operating Cash Flow
-$30M
Beta
0.92
Next Earnings
Oct 30, 2025
Ex-Dividend
N/A
Next Dividend
N/A
BDSX Overview
Biodesix, Inc. operates as a data-driven diagnostic solutions provider. Biodesix offers blood-based tests to assess the risk of lung cancer, identify the appropriate treatment pathway, and help physicians to reclassify the risk of malignancy in patients with suspicious lung nodules. Biodesix was incorporated in 2005 and is headquartered in Boulder, CO.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BDSX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
C
BDSX
Ranked#42 of 44
Ranked#42 of 44
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $151.60 | A | |
| $16.30 | B | |
| $645.65 | B |
Be the first to know about important BDSX news, forecast changes, insider trades & much more!
BDSX News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BDSX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BDSX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BDSX is poor value based on its book value relative to its share price (42.26x), compared to the US Diagnostics & Research industry average (3.78x)
P/B vs Industry Valuation
BDSX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BDSX due diligence checks available for Premium users.
Valuation
BDSX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.17x
Industry
20.81x
Market
37.55x
BDSX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
42.26x
Industry
3.78x
BDSX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BDSX's financial health
Profit margin
Revenue
$20.0M
Net Income
-$11.5M
Profit Margin
-57.3%
BDSX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
BDSX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$87.7M
Liabilities
$86.6M
Debt to equity
76.1
BDSX's short-term assets ($32.45M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BDSX's long-term liabilities ($71.44M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BDSX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BDSX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.6M
Investing
-$95.0k
Financing
$9.8M
BDSX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BDSX vs Diagnostic & Research Stocks
Biodesix Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.